


Accepted Manuscript

Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases

Eric Espinosa, Salvatore Valitutti, Michel Laroche, Camille Laurent, Pol André Apoil, Olivier Hermine, Michel Lavit, Carle Paul, Cristina Bulai Livideanu



PII: S1521-6616(18)30314-0
DOI: doi:[10.1016/j.clim.2018.07.004](https://doi.org/10.1016/j.clim.2018.07.004)
Reference: YCLIM 8067

To appear in: *Clinical Immunology*

Received date: 4 May 2018
Revised date: 5 July 2018
Accepted date: 5 July 2018

Please cite this article as: Eric Espinosa, Salvatore Valitutti, Michel Laroche, Camille Laurent, Pol André Apoil, Olivier Hermine, Michel Lavit, Carle Paul, Cristina Bulai Livideanu, Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases. *Yclim* (2018), doi:[10.1016/j.clim.2018.07.004](https://doi.org/10.1016/j.clim.2018.07.004)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases

Eric Espinosa, PhD¹, Salvatore Valitutti, MD¹, Michel Laroche, MD, PhD², Camille Laurent, MD³, Pol André Apoil, MD, PhD⁴, Olivier Hermine, MD, PhD⁵, Michel Lavit, PharmD⁶, Carle Paul, MD, PhD⁷, Cristina Bulai Livideanu, MD, MSc^{1,7}

¹Inserm, U1037, Centre de Recherche en Cancérologie de Toulouse (CRCT), Toulouse, F-31037, France.

¹Université de Toulouse, Université Paul Sabatier, Toulouse, F-31062, France

²Department of Rheumatology, Toulouse University and CHU, Toulouse, France

³Department of Pathology, Institut Universitaire du Cancer, Toulouse Oncopole, University of Toulouse III Paul Sabatier, Toulouse, France

⁴Immunology Laboratory, Toulouse University Hospital, Toulouse, France

⁵CEREMAST, Department of Hematology, Necker Hospital, Paris-APH, Paris, France

⁶Pharmacokinetics and toxicology Laboratory, Toulouse University and CHU, Toulouse, France

⁷Paul Sabatier University, Mastocytosis National Reference Center (CEREMAST), Department of Dermatology, Toulouse University and CHU, Toulouse, France

Corresponding Author: Cristina Bulai Livideanu, CEREMAST, Department of Dermatology, Toulouse University and CHU, 24 Chemin de Pouvoirville TSA 30030 31059 Toulouse Cedex 9 and Inserm, U1043, Toulouse, F-31300, France, CPTP, Toulouse, F-31300, France, Phone: +33 567778135, Fax: +33 567778136, E-mail: livideanu.c@chu-toulouse.fr

Download English Version:

<https://daneshyari.com/en/article/8721221>

Download Persian Version:

<https://daneshyari.com/article/8721221>

[Daneshyari.com](https://daneshyari.com)